165 related articles for article (PubMed ID: 20138057)
1. Antigenic characteristics of rhinovirus chimeras designed in silico for enhanced presentation of HIV-1 gp41 epitopes [corrected].
Lapelosa M; Arnold GF; Gallicchio E; Arnold E; Levy RM
J Mol Biol; 2010 Apr; 397(3):752-66. PubMed ID: 20138057
[TBL] [Abstract][Full Text] [Related]
2. In silico vaccine design based on molecular simulations of rhinovirus chimeras presenting HIV-1 gp41 epitopes.
Lapelosa M; Gallicchio E; Arnold GF; Arnold E; Levy RM
J Mol Biol; 2009 Jan; 385(2):675-91. PubMed ID: 19026659
[TBL] [Abstract][Full Text] [Related]
3. Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope.
Arnold GF; Velasco PK; Holmes AK; Wrin T; Geisler SC; Phung P; Tian Y; Resnick DA; Ma X; Mariano TM; Petropoulos CJ; Taylor JW; Katinger H; Arnold E
J Virol; 2009 May; 83(10):5087-100. PubMed ID: 19279101
[TBL] [Abstract][Full Text] [Related]
4. Chimeric rhinoviruses displaying MPER epitopes elicit anti-HIV neutralizing responses.
Yi G; Lapelosa M; Bradley R; Mariano TM; Dietz DE; Hughes S; Wrin T; Petropoulos C; Gallicchio E; Levy RM; Arnold E; Arnold GF
PLoS One; 2013; 8(9):e72205. PubMed ID: 24039745
[TBL] [Abstract][Full Text] [Related]
5. ELNKWA-epitope specific antibodies induced by epitope-vaccine recognize ELDKWA- and other two neutralizing-resistant mutated epitopes on HIV-1 gp41.
Dong XN; Xiao Y; Chen YH
Immunol Lett; 2001 Jan; 75(2):149-52. PubMed ID: 11137140
[TBL] [Abstract][Full Text] [Related]
6. Structure-affinity relationships in the gp41 ELDKWA epitope for the HIV-1 neutralizing monoclonal antibody 2F5: effects of side-chain and backbone modifications and conformational constraints.
Tian Y; Ramesh CV; Ma X; Naqvi S; Patel T; Cenizal T; Tiscione M; Diaz K; Crea T; Arnold E; Arnold GF; Taylor JW
J Pept Res; 2002 Jun; 59(6):264-76. PubMed ID: 12010517
[TBL] [Abstract][Full Text] [Related]
7. A predefined epitope-specific monoclonal antibody recognizes ELDEWA-epitope just presenting on gp41 of HIV-1 O clade.
Huang J; Dong X; Liu Z; Qin L; Chen YH
Immunol Lett; 2002 Dec; 84(3):205-9. PubMed ID: 12413738
[TBL] [Abstract][Full Text] [Related]
8. Induction of high levels of antibodies recognizing the neutralizing epitope ELDKWA and the D- or K-position-mutated epitopes by candidate epitope vaccines against HIV-1.
Xiao Y; Dong X; Chen Y
Int Arch Allergy Immunol; 2000 Aug; 122(4):287-92. PubMed ID: 10971120
[TBL] [Abstract][Full Text] [Related]
9. Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5.
Parker CE; Deterding LJ; Hager-Braun C; Binley JM; Schülke N; Katinger H; Moore JP; Tomer KB
J Virol; 2001 Nov; 75(22):10906-11. PubMed ID: 11602730
[TBL] [Abstract][Full Text] [Related]
10. Human Rhinovirus Presenting 4E10 Epitope of HIV-1 MPER Elicits Neutralizing Antibodies in Human ICAM-1 Transgenic Mice.
Yi G; Tu X; Bharaj P; Guo H; Zhang J; Shankar P; Manjunath N
Mol Ther; 2015 Oct; 23(10):1663-70. PubMed ID: 26061648
[TBL] [Abstract][Full Text] [Related]
11. The recombinant immunogen with high-density epitopes of ELDKWA and ELDEWA induced antibodies recognizing both epitopes on HIV-1 gp41.
Wang Z; Liu Z; Cheng X; Chen YH
Microbiol Immunol; 2005; 49(8):703-9. PubMed ID: 16113499
[TBL] [Abstract][Full Text] [Related]
12. Progress towards the development of a HIV-1 gp41-directed vaccine.
McGaughey GB; Barbato G; Bianchi E; Freidinger RM; Garsky VM; Hurni WM; Joyce JG; Liang X; Miller MD; Pessi A; Shiver JW; Bogusky MJ
Curr HIV Res; 2004 Apr; 2(2):193-204. PubMed ID: 15078183
[TBL] [Abstract][Full Text] [Related]
13. N-terminal residues of an HIV-1 gp41 membrane-proximal external region antigen influence broadly neutralizing 2F5-like antibodies.
Li D; Liu J; Zhang L; Xu T; Chen J; Wang L; Zhao Q
Virol Sin; 2015 Dec; 30(6):449-56. PubMed ID: 26715302
[TBL] [Abstract][Full Text] [Related]
14. Induction of HIV-1 broad neutralizing antibodies in 2F5 knock-in mice: selection against membrane proximal external region-associated autoreactivity limits T-dependent responses.
Verkoczy L; Chen Y; Zhang J; Bouton-Verville H; Newman A; Lockwood B; Scearce RM; Montefiori DC; Dennison SM; Xia SM; Hwang KK; Liao HX; Alam SM; Haynes BF
J Immunol; 2013 Sep; 191(5):2538-50. PubMed ID: 23918977
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb.
McGaughey GB; Citron M; Danzeisen RC; Freidinger RM; Garsky VM; Hurni WM; Joyce JG; Liang X; Miller M; Shiver J; Bogusky MJ
Biochemistry; 2003 Mar; 42(11):3214-23. PubMed ID: 12641452
[TBL] [Abstract][Full Text] [Related]
16. Isotype modulates epitope specificity, affinity, and antiviral activities of anti-HIV-1 human broadly neutralizing 2F5 antibody.
Tudor D; Yu H; Maupetit J; Drillet AS; Bouceba T; Schwartz-Cornil I; Lopalco L; Tuffery P; Bomsel M
Proc Natl Acad Sci U S A; 2012 Jul; 109(31):12680-5. PubMed ID: 22723360
[TBL] [Abstract][Full Text] [Related]
17. Multifaceted consequences of anti-gp41 monoclonal antibody 2F5 binding to HIV type 1 virions.
Neurath AR; Strick N; Lin K; Jiang S
AIDS Res Hum Retroviruses; 1995 Jun; 11(6):687-96. PubMed ID: 7576928
[TBL] [Abstract][Full Text] [Related]
18. Multiepitope vaccines intensively increased levels of antibodies recognizing three neutralizing epitopes on human immunodeficiency virus-1 envelope protein.
Lu Y; Xiao Y; Ding J; Dierich MP; Chen YH
Scand J Immunol; 2000 May; 51(5):497-501. PubMed ID: 10792842
[TBL] [Abstract][Full Text] [Related]
19. Induction of monoclonal antibody with predefined ELNKWA epitope specificity by epitope vaccine.
Xiao Y; Dong XN; Chen YH
Hybridoma; 2000 Aug; 19(4):347-50. PubMed ID: 11001409
[TBL] [Abstract][Full Text] [Related]
20. Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus.
Eckhart L; Raffelsberger W; Ferko B; Klima A; Purtscher M; Katinger H; Rüker F
J Gen Virol; 1996 Sep; 77 ( Pt 9)():2001-8. PubMed ID: 8810996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
